Seed funding
Inserm Transfer Initiative and G1J-Ile de France completed the seed financing round of DNA Therapeutics SA, an Institut Marie Curie spin-out set up in May 2006 to commercialise anti-cancer therapies based on signal-interfering DNA. Other investors were Blue Medical Investment Group and International Business Angels.
Tumor cells have a very high capacity to repair damage to their DNA and thus escape the effects of chemo- and radiotherapies. SiDNA is proposed as a method for interrupting the DNA repair pathways that lead tumours to develop such resistance.
Following completion of the seed funding, the company is now looking to raise a first round to finance a clinical trial of its lead product, DBait.
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
